🇺🇸 FDA
Pipeline program

LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR

OTL-203-02

Phase 3 small_molecule active

Quick answer

LARONIDASE, OTL-203, -, RITUXIMAB, FLUDARABINE, BUSULFAN, PLERIXAFOR for Mucopolysaccharidosis type I, Hurler Syndrome is a Phase 3 program (small_molecule) at Orchard Therapeutics (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Orchard Therapeutics (Netherlands) B.V.
Indication
Mucopolysaccharidosis type I, Hurler Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials